Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Gynecology

Standard of Care and Treatment Options

At a Glance

Treatment for postmenopausal atrophic vaginitis typically follows a tiered approach. Mild symptoms are managed with non-hormonal moisturizers. For moderate-to-severe symptoms, low-dose vaginal estrogen is the gold standard, with alternative medications like DHEA and ospemifene available.

Treating Genitourinary Syndrome of Menopause (GSM) is not a “one-size-fits-all” process. Because the condition is progressive, the goal is to find a treatment that both relieves your current symptoms and supports the long-term health of your urogenital tissues [1][2]. Medical guidelines from groups like The Menopause Society (NAMS) generally suggest a tiered approach based on the severity of your symptoms [3].

Tier 1: Non-Hormonal Support

For mild symptoms or for those who prefer to avoid hormones, non-hormonal options are the first step [3]. It is important to know that while these improve comfort, they do not reverse the underlying tissue thinning [4].

  • Vaginal Lubricants: These are used “as needed” specifically during sexual activity [5]. They reduce friction and immediate discomfort but do not provide long-lasting moisture [6].
  • Vaginal Moisturizers: Unlike lubricants, these are used regularly (usually 2–3 times per week) to trap moisture in the vaginal tissues [7][8]. Regular use can improve daily dryness and overall tissue quality [7].

Tier 2: The “Gold Standard” (Low-Dose Vaginal Estrogen)

For moderate-to-severe symptoms, low-dose vaginal estrogen is considered the most effective treatment [1][9]. It works by directly “feeding” the estrogen-starved tissues, restoring the lining, and returning the vagina to a healthy, acidic pH [10][11].

  • Delivery Methods: These treatments are available as creams (which can be somewhat messy but are excellent for treating external vulvar tissue), tablets or inserts (which are less messy and inserted directly into the vagina), and rings (which are inserted and left in place for 3 months, offering a lower-maintenance option) [12].
  • What to Expect (The Timeline): Rebuilding tissue takes time. The typical treatment schedule requires a loading phase of daily application for 1 to 2 weeks, followed by a maintenance schedule of twice a week [1]. It generally takes 2 to 12 weeks of consistent use to fully restore tissue elasticity and reverse symptoms [11].
  • Initial Side Effects: During the first few weeks, you may experience increased discharge, mild burning, or minor spotting [12]. This is a normal reaction as the delicate, atrophic tissue begins to heal and should resolve as the tissue thickens.
  • Local Action, Not Systemic: These treatments use a very small amount of hormone and generally do not significantly raise the level of estrogen in your bloodstream [13][12].
  • Safety Profile: For most women, low-dose vaginal estrogen is considered safe and is not associated with an increased risk of blood clots, heart disease, or cancer [9][14].

FDA-Approved Alternatives

If you prefer not to use estrogen or if it isn’t the right fit for you, there are other targeted medical options:

  • Vaginal DHEA (Prasterone): This is a daily vaginal insert [15]. DHEA is a “precursor” that your vaginal cells convert into exactly the amount of estrogen and androgen they need [16]. Like local estrogen, it works primarily within the tissue and requires consistent daily use to maintain tissue health [13].
  • Ospemifene (Oral Pill): This is a daily pill for those who prefer not to use vaginal inserts [17]. It is a SERM (Selective Estrogen Receptor Modulator). While it acts like estrogen on the vaginal tissues to improve thickness and moisture, it is important to know its safety profile. Ospemifene carries an FDA Boxed Warning because it acts as an estrogen agonist in the endometrium (the lining of the uterus), increasing the risk of endometrial cancer, as well as cardiovascular disorders like deep vein thrombosis (DVT) and stroke [17][18]. Anyone taking this medication must immediately report any unusual vaginal bleeding or spotting to their doctor. Additionally, Ospemifene can cause or worsen hot flashes, an important consideration if you struggle with vasomotor symptoms [17].

A Note for Cancer Survivors

If you have a history of hormone-sensitive breast or endometrial cancer, your treatment plan requires close coordination with your oncologist [19][20]. While non-hormonal options are the first choice, local hormonal treatments may be considered in certain situations if symptoms are severe and other options have failed [20][21].

Common questions in this guide

What is the difference between vaginal lubricants and moisturizers?
Vaginal lubricants are used only during sexual activity to reduce immediate friction and discomfort. Vaginal moisturizers, however, are used regularly throughout the week to trap moisture in the tissues and improve daily comfort.
How long does it take for vaginal estrogen to work?
Rebuilding vaginal tissue takes time. While you may notice some early relief, it generally takes two to twelve weeks of consistent use to fully restore tissue elasticity and reverse symptoms.
What are the side effects of starting vaginal estrogen?
During the first few weeks of using vaginal estrogen, you may experience increased discharge, mild burning, or minor spotting. This is a normal reaction as the delicate, thinned tissue begins to heal, and these symptoms typically resolve as the tissue thickens.
Is low-dose vaginal estrogen safe?
For most women, low-dose vaginal estrogen is considered safe. It uses a very small amount of hormone that works locally in the vaginal tissue and generally does not significantly raise the level of estrogen in your bloodstream.
Are there non-estrogen prescription medications for vaginal dryness?
Yes. If you prefer to avoid direct estrogen, FDA-approved alternatives include vaginal DHEA (prasterone) inserts and ospemifene, a daily oral pill. These targeted medical options can also improve tissue thickness and moisture.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given the severity of my symptoms, should I start with non-hormonal moisturizers or am I a candidate for low-dose vaginal estrogen?
  2. 2.If we choose vaginal estrogen, which formulation—cream, tablet, or ring—would you recommend for my lifestyle and symptoms?
  3. 3.Am I a candidate for a lower-maintenance option like a vaginal ring?
  4. 4.How does the systemic absorption of low-dose vaginal estrogen compare to traditional hormone replacement therapy (HRT)?
  5. 5.Is vaginal DHEA (prasterone) a better option for me if I want to avoid direct estrogen or if I have specific concerns about sexual function?
  6. 6.If I have a history of breast cancer or blood clots, what is the safest way to manage these progressive tissue changes?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Menopausal Hormone Therapy-Risks, Benefits and Emerging Options: A Narrative Review.

    Arnautu AM, Nimigean VR, Nacea-Radu CA, et al.

    International journal of molecular sciences 2025; (26(22)) doi:10.3390/ijms262211098.

    PMID: 41303580
  2. 2

    Treating Genitourinary Syndrome of Menopause in Postmenopausal Women with a History of Breast Cancer.

    Ferguson D, Pederson H, Kling JM

    Drugs & aging 2026; (43(3)):211-221 doi:10.1007/s40266-026-01287-9.

    PMID: 41758440
  3. 3

    What should guide our patient management of vulvovaginal atrophy?

    Shapiro M

    Climacteric : the journal of the International Menopause Society 2019; (22(1)):38-43 doi:10.1080/13697137.2018.1527306.

    PMID: 30452294
  4. 4

    Hormonal Treatments and Vaginal Moisturizers for Genitourinary Syndrome of Menopause : A Systematic Review.

    Danan ER, Sowerby C, Ullman KE, et al.

    Annals of internal medicine 2024; (177(10)):1400-1414 doi:10.7326/ANNALS-24-00610.

    PMID: 39250810
  5. 5

    Prospective, multicenter, uncontrolled study on the effectiveness and safety of a hyaluronic acid water-based vaginal lubricant in alleviating vaginal dryness and dyspareunia.

    Sánchez-Prieto M, Pingarrón C, Bergamaschi L, et al.

    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2024; (40(1)):2317268 doi:10.1080/09513590.2024.2317268.

    PMID: 38468593
  6. 6

    A randomized trial on the effectiveness and safety of 5 water-based personal lubricants.

    Palacios S, Hood S, Abakah-Phillips T, et al.

    The journal of sexual medicine 2023; (20(4)):498-506 doi:10.1093/jsxmed/qdad005.

    PMID: 36781402
  7. 7

    An open, single center, clinical investigation to evaluate the efficacy and safety of a non-hormonal vaginal moisturizer for the symptomatic treatment of vulvovaginal atrophy in postmenopausal woman.

    Sánchez-Prieto M, Mendoza N, Chedraui P, et al.

    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2025; (41(1)):2500480 doi:10.1080/09513590.2025.2500480.

    PMID: 40323284
  8. 8

    Efficacy and safety of a non-hormonal intravaginal moisturizer for the treatment of vaginal dryness in postmenopausal women with sexual dysfunction.

    Vale F, Rezende C, Raciclan A, et al.

    European journal of obstetrics, gynecology, and reproductive biology 2019; (234()):92-95 doi:10.1016/j.ejogrb.2018.12.040.

    PMID: 30677618
  9. 9

    Vaginal estrogen use and chronic disease risk in the Nurses' Health Study.

    Bhupathiraju SN, Grodstein F, Stampfer MJ, et al.

    Menopause (New York, N.Y.) 2018; (26(6)):603-610 doi:10.1097/GME.0000000000001284.

    PMID: 30562320
  10. 10

    Efficacy and safety of an ultra-low-dose 0.005 % estriol vaginal gel in the prevention of urinary tract infections in postmenopausal women with genitourinary syndrome of menopause: A randomized double-blind placebo-controlled trial.

    Muiños Fernández N, Martínez Salamanca JI, Pardo González de Quevedo JI, et al.

    Maturitas 2024; (190()):108128 doi:10.1016/j.maturitas.2024.108128.

    PMID: 39388913
  11. 11

    Vaginal estrogen in the treatment of genitourinary syndrome of menopause and risk of endometrial cancer: an assessment of recent studies provides reassurance.

    Pinkerton JV, Kaunitz AM, Manson JE

    Menopause (New York, N.Y.) 2017; (24(12)):1329-1332 doi:10.1097/GME.0000000000000996.

    PMID: 29040220
  12. 12

    Safety of vaginal estrogens: a systematic review.

    Crandall CJ, Diamant A, Santoro N

    Menopause (New York, N.Y.) 2020; (27(3)):339-360 doi:10.1097/GME.0000000000001468.

    PMID: 31913230
  13. 13

    Managing Genitourinary Syndrome of Menopause in Breast Cancer Survivors Receiving Endocrine Therapy.

    Sussman TA, Kruse ML, Thacker HL, Abraham J

    Journal of oncology practice 2019; (15(7)):363-370 doi:10.1200/JOP.18.00710.

    PMID: 31291563
  14. 14

    Vaginal estrogen use in breast cancer survivors: a systematic review and meta-analysis of recurrence and mortality risks.

    Beste ME, Kaunitz AM, McKinney JA, Sanchez-Ramos L

    American journal of obstetrics and gynecology 2025; (232(3)):262-270.e1 doi:10.1016/j.ajog.2024.10.054.

    PMID: 39521301
  15. 15

    Science of intracrinology in postmenopausal women.

    Labrie F, Bélanger A, Pelletier G, et al.

    Menopause (New York, N.Y.) 2017; (24(6)):702-712 doi:10.1097/GME.0000000000000808.

    PMID: 28098598
  16. 16

    The vagina as source and target of androgens: implications for treatment of GSM/VVA, including DHEA.

    Cipriani S, Maseroli E, Ravelli SA, Vignozzi L

    Climacteric : the journal of the International Menopause Society 2023; (26(4)):309-315 doi:10.1080/13697137.2023.2213827.

    PMID: 37288964
  17. 17

    Ospemifene: A Novel Oral Therapy for Vulvovaginal Atrophy of Menopause.

    Reid RL, Black D, Derzko C, Portman D

    Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC 2020; (42(3)):301-303 doi:10.1016/j.jogc.2019.10.039.

    PMID: 31932249
  18. 18

    Clinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophy.

    Palacios S, Cancelo MJ

    International journal of women's health 2016; (8()):617-626 doi:10.2147/IJWH.S110035.

    PMID: 27822125
  19. 19

    WISDOM survey: attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history.

    Kingsberg SA, Larkin L, Krychman M, et al.

    Menopause (New York, N.Y.) 2019; (26(2)):124-131 doi:10.1097/GME.0000000000001194.

    PMID: 30130293
  20. 20

    Vaginal Estrogen Therapy Use and Survival in Females With Breast Cancer.

    McVicker L, Labeit AM, Coupland CAC, et al.

    JAMA oncology 2024; (10(1)):103-108 doi:10.1001/jamaoncol.2023.4508.

    PMID: 37917089
  21. 21

    Genitourinary syndrome of menopause in women with cancer - a narrative review.

    Ryan HM, Brennan DJ

    Maturitas 2026; (211()):109004 doi:10.1016/j.maturitas.2026.109004.

    PMID: 42224847

This page provides educational information about treatments for postmenopausal atrophic vaginitis. It does not replace professional medical advice. Always consult your doctor or gynecologist before starting any hormonal or non-hormonal therapy.

Get notified when new evidence is published on postmenopausal atrophic vaginitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.